SpaceX (NSDQ:SPCX) The Most Misunderstood US $2T IPO in Decades
Should you buy SpaceX
SpaceX is becoming one of the most misunderstood IPOs in market…
- ASX: NTI
Neurotech International
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Company Overview
About Neurotech International
Neurotech International is an Australian biotechnology company focused on developing and commercialising treatments for neurological and mental health conditions. The company is primarily working on NTI164, a cannabis-derived therapy aimed at treating paediatric neurological disorders such as Autism Spectrum Disorder (ASD), PANDAS/PANS, Rett Syndrome, and spastic cerebral palsy. Preclinical and clinical studies have vindicated not just that it can work, but that it addresses the underlying causes and not just symptoms.
NTI Company History
Neurotech was founded with a vision to address critical gaps in the treatment of neurological and mental health disorders. It acquired a Malta-based company (AAT Research) that had Mente Autism, a home-based device to relax kids’ minds and listed – events that occurred in 2016. While Mente was approved by the TGA, things fell apart in 2019 when it turned out that the founder of AAT Research did not have a Doctorate of Philosophy in neuroscience and he was terminated. Mente’s TGA registration was cancelled. NTI then pivoted to a unique cannabis strain that it thought could address autism (NTI-164). Now, it has expanded into Rett Syndrome, the same disorder Neuren is targeting. Phase I/II results were positive in both indications and the company is now targeting a larger trial that could see it receive regulatory approval, in autism.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook of Neurotech International (ASX: NTI)
Looking ahead, Neurotech International is well-placed to benefit from the need for efficacious neurological treatments. The company estimates it has a >US$10bn TAM across all indications and that’s assuming conservative pricing and a mere 1% market share. NTI is aiming for a provisional Australian determination and US Independent New Drug approval in the US by the end of 2025. It aims for TGA approval by the end of 2026, and for first revenues in 2027. Beforehand, the company hopes to have secured a partnering and/or licensing deal. As good as this sounds, the company’s fate is susceptible to regulators and the success of clinical trials. A lack of ability to stick with these timelines could be fatal to its future.
— Our Assessment
Is NTI a Good Stock to Buy?
Neurotech International presents an intriguing investment opportunity. It is attacking a neurological disorder (Rett) that made investors in Neuren rich, and it has the additional angle of bringing a medicinal cannabis drug to market. However, when considering whether to buy NTI stock, there are several important factors to keep in mind. The most important of which is whether or not it can stay on track with its timelines. NTI has significant growth potential, especially as its treatment moves closer to commercialisation, but it is also high risk.
— Our Stock Analysis
Related Articles
Qualcomm in Talks to Buy Tenstorrent for US$10bn, Lifting 3 ASX AI Chip Stocks
KEY POINTS
Qualcomm (NASDAQ:QCOM) is in talks to buy AI chip startup Tenstorrent for…
Southern Cross Electrical (ASX:SXE) Raises $150m and Upgrades Guidance as Data Centre Demand Surges
KEY POINTS
Southern Cross Electrical (ASX:SXE) came back from a trading halt with a…
SpaceX (NSDQ:SPCX) prices US$135 IPO as orbital AI becomes the story
SpaceX (NSDQ:SPCX) prices its IPO at US$135 per share, with the orbital AI compute pitch…
Oracle (NYSE:ORCL) Shares Fall 7% Despite the Beat as Red Flags Build
Beats Expectations, But the 7% Sell-Off Exposes Bigger Risks
Following our Q3 FY26 report, which…
X2M Connect (ASX:X2M) signs Resi Ventures and opens a A$3.6bn door
X2M Connect (ASX:X2M) signs a five-year partnership with Resi Ventures to manage integrated regional data…
— Faq
Frequently Asked Questions
What is the dividend yield of Neurotech International?
Neurotech International does not currently offer a dividend, as it is focused on reinvesting earnings into its research and development efforts.
How does NTI compare to its peers?
NTI stands out from its peers in the biotechnology and medical cannabis sectors by focusing on cannabinoid-based treatments for neurological and mental health disorders. While many companies operate in similar spaces, NTI’s research partnerships and pipeline development set it apart.
What are the risks of investing in NTI?
The main risks include regulatory uncertainty surrounding medical cannabis, the outcome of clinical trials, and market competition. As with most biotechnology stocks, NTI’s future is tied to the success of its research and product approval.
What is the future outlook for NTI?
NTI’s future looks promising, with ongoing clinical trials and a growing market for medical cannabis treatments. The company’s expansion into international markets and strategic partnerships will be key drivers of its future growth.
Is Neurotech International a good investment?
For investors seeking exposure to the growing medical cannabis market, NTI presents an attractive growth opportunity. However, given its early-stage development and the inherent risks in the biotechnology sector, it may be more suitable for those with a higher risk tolerance.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
